Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that is either triple-negative or HR+/HER2- and has gotten worse after treatment.
- Your cancer can be measured on a CT scan or MRI.
- If you have brain metastases, they must be treated and stable without needing high-dose steroids for at least 2 weeks.
- You do not have an active autoimmune disease (except mild skin conditions like vitiligo or psoriasis not requiring strong medication).
- You have not had major surgery or an unhealed wound in the past 8 weeks.
- You are not pregnant or breastfeeding, and you are willing to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.